A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3 - Related Studies

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

This study has been completed.

Study NCT00002106. Last updated on June 23, 2005. Information provided by NIH AIDS Clinical Trials Information Service

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Infection

3	More general conditions related to this trial
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Ranitidine hydrochloride

5	Additional drug interventions recognized in this trial
		Ranitidine
		Ranitidine bismuth citrate

6	More general drug interventions related to this trial
		Anti-Ulcer Agents
		Gastrointestinal Agents
		Histamine Agents
		Histamine Antagonists
		Histamine H2 Antagonists
		Molecular Mechanisms of Pharmacological Action
		Neurotransmitter Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Glaxo Wellcome